THE COVER STORY • VIETNAM

GCEIP



From Genomics Research to Regional Diagnostics Business: Nguyen Hoai Nghia's Next Test

Enabling Early Detection Through Ecosystem Engagement

The Gene Solutions co-founder is extending a Vietnam-born genetic-testing business across Asia, while leadership, learning and growth reach beyond laboratory science to clinical evidence, responsible growth and international expansion.

GCEIP Editorial Desk · 13 November 2026

Bringing genomics expertise home

From Vietnam to a regional lab network

The Decision to Bring the Science Home

Nguyen Hoai Nghia could have continued a research career in the United States. Instead, the Vietnamese scientist returned to help build a company around a difficult question: could advanced genetic testing become more accessible to patients and clinicians in Vietnam and across the region?

He co-founded Gene Solutions in 2017 with Nguyen Huu Nguyen and Giang Hoa. Their backgrounds in genetics, clinical medicine and data science gave the young business an unusual starting point. This was not a conventional consumer technology startup. Its products would require laboratory infrastructure, scientific validation and confidence from medical professionals before they could become commercially useful.

THE SCIENCE OF SCALE

Nguyen Hoai Nghia

Nghia, now chairman and chief executive, had to build a bridge between scientific research and an operating diagnostics company. That meant much more than moving a test from a laboratory bench onto a website. Gene Solutions needed trained personnel, reliable testing processes, hospital relationships and systems for handling sensitive clinical information.

From a Domestic Business to a Regional Network

Gene Solutions developed services in prenatal genetic screening and oncology-related testing. Its company history describes a progression from Vietnam-focused offerings to a broader portfolio of molecular testing and partnerships across Asian markets.

The regional transition became more visible in 2025 and 2026. In a 2025 Reuters report, the company and investor Mekong Capital described plans to raise capital ahead of a potential public listing. In a June 2026 interview reported by Bloomberg, Nghia discussed a possible Hong Kong listing in 2027 and further international expansion. These were plans, not a completed IPO or a guaranteed transaction.

The distinction matters. For science-led businesses, announcements about financing and new markets are not proof that execution has been completed. New geographies introduce different healthcare systems, reimbursement arrangements, medical regulations and operating partners. Commercial growth also needs to be matched by demonstrable clinical quality.

Gene Solutions' published leadership information now identifies operations or markets spanning Southeast Asia and beyond. Nghia's strategic opportunity is to turn that footprint into a repeatable model that retains the trust of physicians and patients while maintaining rigorous laboratory practices.

The Business Beneath the Breakthrough

Genetic diagnostics occupies a demanding intersection of medicine, technology and enterprise-building. The underlying sequencing and computational capabilities are sophisticated, but a business built around them must answer practical questions. Can a clinician understand the clinical purpose and limitations of each test? Can samples be processed consistently? Are patient data protected? Can a service be delivered affordably without overstating what its results establish?

These are not secondary issues. They determine whether a technically promising company earns long-term credibility. For Nghia, leadership involves allocating resources between research, laboratory operations, scientific validation, commercial relationships and regulatory compliance. Pursuing all of them simultaneously can create tension between expansion and discipline.

The company's work also sits in a field where medical claims require care. Screening is not the same as definitive diagnosis, and different tests have different clinical uses and limitations. Any account of Gene Solutions must distinguish company aspirations from independently validated performance.

GCEIP Analysis

The noteworthy transformation is not simply that Nghia founded a biotechnology company. It is that a research-led Vietnamese venture is attempting to scale specialist diagnostics internationally while preserving the standards that healthcare demands.

His decision to return home created an opportunity to develop local scientific talent and laboratory capabilities. The more complex task now is institutional: management systems, cross-border partnerships, transparent evidence and a commercial model resilient enough to support continuous research.

Investors may value market growth, but doctors and patients ultimately judge a diagnostic business by quality, clarity and reliability. Those measures should remain central as Gene Solutions develops its next phase.

GCEIP View

Nguyen Hoai Nghia represents a form of emerging Asian leadership in which scientific expertise must evolve into enterprise-building capability. Gene Solutions' regional ambitions make his story relevant well beyond Vietnam, yet a proposed listing and international footprint are milestones to evaluate, not substitutes for evidence of impact.

The leadership test ahead is whether Nghia can make advanced diagnostics more accessible while maintaining clinical trust, responsible claims and consistent execution. That is a transformation worth following—and one that should be judged by the durability of the institution he helps build.